Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns
An unlicensed semaglutide-based product that is administered under the tongue is being marketed to private doctors in the UK despite…
31 Jul 2026
J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout
Johnson & Johnson (J&J) is venturing further into the increasingly crowded in vivo CAR-T market, this time through an autoimmune drug development and potential acquisition deal with Sail Biomedicines. Together,…
31 Jul 2026
miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond…
31 Jul 2026
Resilience and Lilly to increase US medicines production with $750m investment
Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly’s KwikPen injectable device in Ohio, aiming to strengthen the…
30 Jul 2026
Pfizer seeks label expansion for Litfulo after double Phase III NSV win
Pfizer’s Litfulo (ritlecitinib) could be set for a label expansion after it met the endpoints of two Phase III studies in both active and stable nonsegmental vitiligo (NSV). The drug…
30 Jul 2026
EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals
European drug regulators have been busy this week – opting to approve several medicines from companies like AbbVie, Pfizer & BioNTech and Incyte across dermatological, infectious disease and immunological indications.…
30 Jul 2026
FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute
A US Food and Drug Administration (FDA) advisory committee meeting (AdCom) has voted against Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD), capping an extraordinary meeting in which the…